Vitaly Margulis, MD
Urology · Dallas, TXNPI 1134152937
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $378,778 of the $555,407 with a category attached, or 68.2%. 36 manufacturers reported payments, led by Johnson & Johnson at 48.2% of the total. 2025 is the largest year on record at $193,997, 3.2 times the $61,216 reported in 2019. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $933.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$268K
- Progenics Pharmaceuticals, Inc.$111K
- Merck$95K
- Urogen Pharma, Inc.$26K
- Janssen Scientific Affairs, LLC$20K
- Blue Earth Diagnostics$7K
- plus $30K from 30 others
Across 8 payments — averaging $151,772 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
What the payments were for
- Consulting fees$69,78413%
- Speaking & faculty fees$378,77868%
- Travel & lodging$89,17216%
- Food & beverage$17,5743%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 262 | $267,927 |
| Progenics Pharmaceuticals, Inc. | 87 | $110,878 |
| Merck | 79 | $94,931 |
| Urogen Pharma, Inc. | 35 | $25,575 |
| Janssen Scientific Affairs, LLC | 8 | $19,789 |
| Blue Earth Diagnostics | 8 | $6,602 |
| AstraZeneca | 12 | $4,678 |
| Eisai Inc. | 1 | $4,100 |
| Avyxa Pharma, LLC | 7 | $3,789 |
| Bayer | 5 | $3,135 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,497 |
| Genentech USA, Inc. | 2 | $2,197 |
| Telix Pharmaceuticals | 4 | $1,791 |
| Intuitive Surgical | 18 | $1,345 |
| Photocure Inc | 7 | $598 |
| Myriad Genetic Laboratories, Inc. | 4 | $597 |
| Dendreon Pharmaceuticals LLC | 3 | $520 |
| Endo Pharmaceuticals Inc. | 1 | $500 |
| Medtronic | 4 | $458 |
| Procept Biorobotics Corporation | 5 | $447 |
| Conmed Corporation | 4 | $439 |
| Boston Scientific | 5 | $367 |
| Stryker | 1 | $350 |
| Dr.reddy's Laboratories,inc. | 1 | $308 |
| Astellas Pharma US Inc | 2 | $244 |
| KARL Storz Endoscopy-america | 4 | $226 |
| Myovant Sciences Inc. | 6 | $180 |
| AVEO Pharmaceuticals, Inc. | 2 | $168 |
| Sumitomo Pharma America, Inc. | 4 | $167 |
| Immunitybio, Inc. | 1 | $150 |
| Foundation Medicine, Inc. | 2 | $139 |
| Laborie Medical Technologies Corp. | 3 | $122 |
| Profound Medical Corp. | 1 | $72 |
| Covidien LP | 1 | $56 |
| Innovation Technologies Inc | 2 | $49 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$555,407 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $9,568 |
| MyrbetriqMirabegron | 13 | $8,051 |
| Tamsulosin Hcl | 148 | $2,262 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 11 | $1,237 |
| Finasteride | 100 | $1,206 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $580 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $549 |
| Methocarbamol | 63 | $322 |
| Oxybutynin Chloride | 32 | $318 |
| Ciprofloxacin Hcl | 34 | $192 |
| Tramadol Hcl | 100 | $161 |
| Cephalexin | 15 | $146 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $128 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 26 | $97 |
| Levofloxacin | 47 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $9,56819 claims |
| Astellas Pharma US IncMyrbetriq | $244 | $8,05113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Allen MoreyDallas$914K
- Yair LotanDallas$371K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.